694 related articles for article (PubMed ID: 30755502)
1. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
2. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
5. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.
Sasaki K; Andreatos N; Margonis GA; He J; Weiss M; Johnston F; Wolfgang C; Antoniou E; Pikoulis E; Pawlik TM
J Surg Oncol; 2016 Dec; 114(7):803-809. PubMed ID: 27792291
[TBL] [Abstract][Full Text] [Related]
6. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.
Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Ozawa T; Yokoyama Y; Nagai Y; Anzai H; Sonoda H; Yamauchi S; Sugihara K; Ishihara S
BMC Cancer; 2022 May; 22(1):486. PubMed ID: 35501727
[TBL] [Abstract][Full Text] [Related]
8. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
9. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
11. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
13. Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis.
Zhang Y; Wang Y; Yuan Y; Qiu J; Qiu Y; He W; Zheng Y; Wang Z; Gu Y; Lu Z; Chen G; Ding P; Wu X; Pan Z; Wan D; Li Y; Xu R; Yuan Y; Li B
World J Surg Oncol; 2020 May; 18(1):98. PubMed ID: 32423450
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
[TBL] [Abstract][Full Text] [Related]
15. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
16. Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.
Korphaisarn K; Sukhokanjanachusak K; Pongpaibul A; Chinswangwatanakul V; Akewanlop C
Asia Pac J Clin Oncol; 2022 Jun; 18(3):249-258. PubMed ID: 34161647
[TBL] [Abstract][Full Text] [Related]
17. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
18. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
19. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
[TBL] [Abstract][Full Text] [Related]
20. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice.
Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]